Partner With Us
Elevate Your Brand to the Leading Minds of Obesity & NASH
Get ahead of the curve and position your company at the forefront of the minds of leading pharma and pioneering biotech at the 7th Obesity & NASH Drug Development Summit; dedicated to pushing the boundaries in cutting-edge metabolic research and drug development using contract research, multi-omics, in vivo and in vitro models, digital pathology, artificial intelligence, and non-invasive biomarkers.
Partner with us to showcase your brand and capitalize on our audience of leading companies with active pipelines in NASH and obesity.
Why Do Partners Return?
Regeneron, Amgen, Gilead, Inventiva, Akero Therapeutics and AstraZeneca are amongst our other 160+ attendees that are seeking partners to help them in the following areas:
Contract Research – accelerate and support preclinical and clinical R&D and position yourself as the leading CRO in metabolic syndromes
Non-Invasive Biomarkers– communicate your capabilities to enhance the development and validation of blood-based, serum, predictive and imaging biomarkers to demonstrate benefit beyond bariatric surgery
Digital Pathology – demonstrate your expertise in quantifying details of fibrosis dynamics with novel insights into treatment-induced fibrosis regression in NASH to accurately diagnose and treat patients
Discovery & Omics – aid industry in clarifying the route towards anti-obesity treatments by offering your services in genotyping of patients and omics-type analyses
Who Will You Meet
Educate the Industry: Secure a speaking position to explain how your solutions can directly support industry challenges in a room full of potential clients
Showcase Your Products: Bypass the crowds in large trade shows and assert your authority by displaying your services with our targeted exhibition space
Gain Brand Visibility: Broaden your company’s exposure with 160+ dedicated delegates Eli Lilly, Novo Nordisk, Amgen, Regeneron, AstraZeneca, Pfizer, and many more in attendance